Authors' objectives:

The objective of this report was to conduct a comprehensive literature review and synthesis of evidence on the use of the supplements vitamin C, vitamin E, and coenzyme Q10 for the treatment and prevention of cancer.

Authors' results and conclusions: We identified 432 articles for screening from which 35 articles met the criteria for inclusion in the analysis. These articles represented 37 unique studies and 22 unique trials, because many studies presented data on the same trial. The identified trials varied greatly in quality. For the doses and populations studied in the trials. There was no evidence found for assessing the efficacy of coenzyme Q10 for prevention or treatment of cancer. We identified three large trials assessing the effect of vitamin C and vitamin E in various combinations given to persons without cancer. No trial reported a statistically significant beneficial effect on death due to cancer. Subgroup analysis did identify a statistically significant 9% reduction in all cause mortality and a borderline significant 13% reduction in all-cancer mortality associated with supplemental vitamin E in combination with other micro- nutrients. All other trials showed no benefit for all other types of new tumor development except for one arm of the ATBC trial, which showed a decrease in the development of new prostate tumors. We identified seven trials that assessed the use of vitamin C in patients with advanced cancer. No trial reported a statistically significant mortality benefit. There was no decrease in risk of death for vitamin C as a treatment for advanced cancer. We identified six trials assessing the effect of combinations of vitamin C and vitamin E with and without beta-carotene on the development of colonic polyps. No trial reported a statistically significant beneficial effect. We identified six unique trials that reported on various intermediate outcomes. The following beneficial results were reported from single trials: Vitamin C was found to be beneficial in reducing the occurrence of new tumors in a single trial of patients with bladder cancer also treated with bacillus Calmetee-Guerin (BCG). Vitamin E in combination with omega-3 fatty acid increases survival in patients severely ill with a variety of malignancies. A number of intermediate outcomes studies were positive.

Authors' recommendations: For the interventions tested, in the populations described, there is scant evidence that vitamin C or vitamin E beneficially affects survival. Similarly, for the interventions tested, in the populations described, there are no results suggesting a benefit for the prevention of new tumors, which reach statistical significance with the exception of prostate cancer in subjects treated with alpha-tocopherol. One trial reported a benefit of a megadose vitamin therapy on the development of new tumors in patients with bladder cancer. However, the ability to infer from this finding is limited because the multi-component intervention limits our ability to attribute the reported efficacy to any particular component. For the outcome for colonic polyps, four trials focusing on secondary polyp recurrence could be pooled for analysis and none used vitamins C or E as a single intervention. The combination of vitamins C and E was not clinically superior to placebo in secondary prevention. The combination of vitamins C and E with beta-carotene or vitamin A did show a trend favoring a reduction in polyp recurrence, but this finding was not statistically significant. The systematic review of the literature does not support the hypothesis that the use of supplements of vitamin C or E or coenzyme Q10 generally help prevent and/or treat cancer. There were isolated findings of benefit, which require confirmation.

Authors' methods: Systematic review

Project Status: Completed

URL for project: http://www.ahrq.gov/clinic/tp/aoxcantp.htm

Year Published: 2003

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: Agency for Healthcare Research and Quality

Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;

Contact Name: martin.erlichman@ahrq.hhs.gov

Contact Email: martin.erlichman@ahrq.hhs.gov

Copyright: Agency for Healthcare Research and Quality (AHRQ)